eXoZymes, Inc.

NASDAQ:EXOZ

Biotechnology

Healthcare
$5.54 +16.75%

+$1.06 today

Market cap
$51.42M
Beta
2.66
P/E (TTM)
-6.5
EPS (TTM)
-$1.14
52W Low $6.33High $18.40

Volume 0.01M

Average 0.01M

EXOZ Total Liabilities

Everything the company owes to creditors and other parties.

eXoZymes, Inc.NASDAQ: EXOZ

Total Liabilities · Q1 FY2026 · quarter ended Mar 2026

Total liabilities falls 5.8% from a year ago

Total liabilities stood at $2.49M at the end of Q1 FY2026, down 5.8% from a year earlier and down 3.2% from the prior quarter. Over 3 fiscal years it compounded at +25.2% a year.

Context

  • Total liabilities amounted to 62.0% of total assets at the end of Q1 FY2026, up 39.0 pp from a year earlier.
  • Total liabilities increased in 1 of the last 3 fiscal years.

What to watch

Whether total liabilities keeps falling in the next quarterly balance sheet after a -5.8% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.49M-3.2% QoQ
Last fiscal yearDec 2025
$2.57M-1.5% YoY
Year agoMar 2025
$2.64M-5.8% since
Total Liabilities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-5.8%——
1 year-1.5%——
3-year CAGR+25.2%——
5-year CAGR——
10-year CAGR——

Total Liabilities history

USD · from the balance sheet

Latest · FY2025
2.57M USD
Year-over-year change
-1.5%
4-year CAGR
+22.3%

Total Liabilities vs competitors

How EXOZ compares with its peers on the latest reported figures

  • Peers report in different currencies, so total liabilities is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -5.8% is the 6th highest of 7, against a peer median of +28.2%.
  • Total liabilities amounts to 62.0% of total assets for EXOZ, versus a peer median of 74.7%.
EXOZ Competitors
Total Liabilities for EXOZ and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
SRZNSurrozen, Inc.Mar 2026$398.86M USD+265.4%+177.3%330.4%
TILInstil Bio, Inc.Mar 2026$89.73M USD-3.0%-8.9%44.8%
ONCYOncolytics Biotech Inc.Mar 2026CA$13.29M CAD+0.6%+13.0%162.9%
TLSATiziana Life Sciences LtdDec 2025$11.44M USD+55.7%+18.3%99.5%
CGTXCognition Therapeutics, Inc.Mar 2026$6.23M USD-44.5%+11.5%17.2%
GLSIGreenwich LifeSciences, Inc.Mar 2026$5.24M USD+263.9%+97.2%49.8%
EXOZeXoZymes, Inc.Mar 2026$2.49M USD-5.8%+25.2%62.0%
Peer median (excluding EXOZ) —+28.2%+15.7%74.7%

Competitors are the stored peer set for EXOZ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents547.81K558.57K66.53K9.72M3.04M
Short-term Investments00000
Net Receivables468.35K809.53K882.32K737.28K517.36K
Inventory00000
Other Current Assets30.19K101.14K264.76K363.79K382.89K
Total Current Assets1.05M1.47M1.21M10.82M3.94M
Property, Plant & Equipment (Net)1.3M1.22M2.34M2.21M2.21M
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets0000(176.77K)
Total Non-current Assets1.3M1.22M2.34M2.21M2.03M
Total Assets2.35M2.69M3.56M13.03M5.97M
Account Payables267.3K385.8K702.91K924.25K1.24M
Short-term Debt00000
Tax Payables063.56K42.27K00
Deferred Revenue00000
Other Current Liabilities001M00
Total Current Liabilities400.78K634.36K2.42M1.33M1.57M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)161.11K215K140.7K00
Other Non-current Liabilities000123.58K90.37K
Total Non-current Liabilities748.25K678.77K1.53M1.28M1.01M
Total Liabilities1.15M1.31M3.94M2.61M2.57M
Common Stock126688
Retained Earnings(2.65M)(4.05M)(6.08M)(11.95M)(21.1M)
Accumulated OCI00000
Other Stockholders Equity00000
Minority Interest00000
Total Equity1.2M1.37M(384.32K)10.42M3.4M
Total Debt720.63K608.77K1.61M1.39M1.24M
Net Debt172.82K50.2K1.55M(8.33M)(1.8M)

eXoZymes, Inc.

NASDAQ:EXOZ

Intrinsic Alpha fair value

Locked

Current Price

$5.54

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.